-Reuters
Related Posts
Immuneering Shares Climb After Pursuing FDA Nod For RAS Mutant Tumor Study
Immuneering (NASDAQ: IMRX) submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for its product candidate IMM-1-104 in development for the treatment of advanced RAS mutant solid tumors.
Tesla Denies Cybertruck Inventory Concerns: ‘We Are Actively Building Foundation Series’
Tesla Inc (NASDAQ: TSLA) employees had reported an unexpected buildup of Foundation Series Cybertruck inventories.
Clovis Oncology Announced Rubraca (Rucaparib) as First-Line Maintenance Treatment Improves Progression-Free Survival in Women with Advanced Ovarian Cancer Across Disease Risk Subgroups; Data Presented at ESMO 2022
Clovis Oncology, Inc. (NASDAQ: CLVS), today announced results from a subgroup analysis of data from the monotherapy comparison of the randomized, Phase 3 ATHENA (GOG-3020/ENGOT-ov45) trial (ATHENA-MONO).